UK markets close in 7 hours 35 minutes

Bayer Aktiengesellschaft (BAYN.DE)

XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
51.70-1.00 (-1.90%)
As of 09:40AM CET. Market open.
Full screen
Previous close52.70
Open52.04
Bid51.68 x 28400
Ask51.73 x 2100
Day's range51.68 - 52.51
52-week range43.90 - 57.73
Volume513,575
Avg. volume2,849,182
Market cap50.791B
Beta (5Y monthly)1.31
PE ratio (TTM)344.67
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield2.00 (3.84%)
Ex-dividend date28 Apr 2021
1y target estN/A
All
News
  • Business Wire

    Andes Raises USD 15 Million in Series A Funding Co-Led by Leaps by Bayer and Cavallo Ventures

    LEVERKUSEN, Germany & EMERYVILLE, Calif., September 14, 2021--Leaps by Bayer, the impact investment arm of Bayer AG, today announced that it has co-led a USD 15 million Series A investment round in agriculture and biotechnology innovator, Andes, with Cavallo Ventures. Other new investors Builders VC, Germin8, Accelr8 and Wilson Sonsini participated, alongside existing investors KdT Ventures and Endurance.

  • EQS Group

    Bayer Aktiengesellschaft: Bayer announces five-point plan to effectively address potential future Roundup(TM) claims

    Bayer Aktiengesellschaft / Key word(s): Statement/Legal MatterBayer Aktiengesellschaft: Bayer announces five-point plan to effectively address potential future Roundup(TM) claims27-May-2021 / 01:06 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Bayer announces five-point plan to effectively address potential future Roundup(TM) claimsLeverkusen, May 27, 2021 - Bayer announced today a series of actions it plans to implement following the denial of the motion to preliminarily approve the Roundup(TM) class settlement agreement, designed to address potential future litigation, by Judge Vince Chhabria of the U.S. District Court for the Northern District of California. The new package of measures, which combine a number of legal and commercial actions, is designed to help the company achieve a level of risk mitigation that is comparable to the previously proposed national class solution.The court's decision closes the door on an MDL court-supervised national class solution to manage potential future litigation, which would have been the fairest, most efficient mechanism for all parties. Still, we have legal and commercial options that together will achieve a similar result in mitigating future litigation risk, and we will pursue them as quickly as possible. Significantly, the weight of scientific evidence and the conclusions of all expert regulators worldwide continue to support the safety of glyphosate-based herbicides. Last week, the U.S. Environmental Protection Agency (EPA) filed a brief with the U.S. Court of Appeals for the 9th Circuit in which it affirmed once again that glyphosate 'poses no human-health risks of concern.' Thus, these actions are being taken exclusively to manage litigation risk and not because of any safety concerns.The five-point plan includes:1. Creation and promotion of a new website with scientific studies relevant to Roundup's(TM) safety, and a request that EPA approves corresponding language on Roundup(TM) labels. This will include a reference link to the label for all Roundup(TM) products that will take consumers and professional users to a website the company will maintain and promote containing scientific studies relevant to the safety concerns at issue in the litigation. Bayer intends to create and maintain this website and promote it to all customer audiences regardless of whether EPA ultimately approves the label addition. Importantly, this website will not make any claims or draw conclusions about the safety of Roundup(TM); instead, in the interest of transparency and accessibility, it would provide a one-stop resource for consumers and professional users to a significant body of scientific study to help them make their own decisions about their use of the products. 2. While the Company will remain in the residential lawn and garden market, it will immediately engage with partners to discuss the future of glyphosate-based products in the U.S. residential market, as the overwhelming majority of claimants in the Roundup(TM) litigation allege that they used Roundup(TM) Lawn and Garden products. None of these discussions will affect the availability of glyphosate-based products in markets for professional and agricultural users.3. Future Claims Settlements and Independent Science Advisory Panel. The company will explore alternative solutions aimed at addressing potential future Roundup(TM) claims. Any such programs would help bring resolution to potential future claims brought by individuals. The company also will explore the creation of an independent scientific advisory panel comprised of external scientific experts to review scientific information regarding the safety of Roundup(TM). The results would be released publicly and added to the website above, actions that reflect both the company's confidence in the safety of Roundup(TM) and its commitment to scientific rigor and transparency.4. Ongoing Efforts to Settle Existing Claims Will Be Reassessed. The company will continue to be open to settlement discussions, as long as claimants are qualified and resolutions can be reached on appropriate terms. This effort to resolve claims amicably is a step the company is taking in good faith to bring an end to the litigation and liability risk, but it will regularly reassess whether this approach continues to serve the company's best interests. In June 2020, Bayer announced a comprehensive resolution to all pending cases and claims and most recently reported that the vast majority of these, approximately 96,000 total claims, have been finalized, are in the final stages of resolution or involve claims that are not eligible.5. Continuing Appeals. While not new actions, the appeals of the Hardeman and Pilliod cases will continue through the legal process and can also help manage future liability risk. The Carson case, now before the 11th Circuit Court of Appeals, also raises the same federal preemption issue - whether state-based failure-to-warn claims can stand if they are different from or conflict with federal law - that is central to this litigation. The company has strong legal arguments on its side and a favorable decision by the U.S. Supreme Court by mid-2022 on cross-cutting issues like preemption or expert evidence would significantly reduce future liability risk.Bayer is confident that this new five-point plan of legal and commercial actions provides an effective path for the company to manage and address any risks from potential future Roundup(TM) litigation.Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.Contact:Mr. Peter Dahlhoff, Bayer AG, Investor Relations, Phone: +49-214-30-33022, e-mail: peter.dahlhoff@bayer.com, Fax: 0214-30-96-33022Information and Explanation of the Issuer to this News:Notes:The following resources are available online www.bayer.com/settlements Speech for the Investor and Media Conference Call Audio recording and transcript (shortly after the conference call) Further information on glyphosateYou can listen to the conference call live. Registration is required: Investor and Media Conference Call on May 27 at 2:30 a.m. EDT (8:30 a.m. CEST), register here: https://services.choruscall.de/DiamondPassRegistration/register?confirmationNumber=7070758&linkSecurityString=b6e20a29a About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.com. 27-May-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Bayer Aktiengesellschaft Kaiser-Wilhelm-Allee 1 51373 Leverkusen Germany Phone: +49 (0)214 30-65742 Fax: +49 (0)21430-9665742 E-mail: ir@bayer.com Internet: www.bayer.com ISIN: DE000BAY0017 WKN: BAY001 Indices: DAX, EURO STOXX 50, Stoxx 50 Listed: Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime Standard), Hamburg, Hanover, Munich, Stuttgart; Regulated Unofficial Market in Tradegate Exchange EQS News ID: 1201105 End of Announcement DGAP News Service